Increasing prevalence of galactose-α-1,3-galactose sensitization in the Danish general adult population
- PMID: 39441524
- PMCID: PMC11724227
- DOI: 10.1111/all.16360
Increasing prevalence of galactose-α-1,3-galactose sensitization in the Danish general adult population
Abstract
Background: Alpha-gal syndrome is a novel food allergy to the oligosaccharide galactose-α-1,3-galactose (alpha-gal) present in mammalian meat. Tick bites are considered an important route of sensitization to alpha-gal. Data on alpha-gal sensitization in the general population is scant. We utilized a unique data source of repeated population-based health examination studies to assess prevalence, time trends, risk factors, and characteristics of alpha-gal sensitization.
Methods: Alpha-gal sensitization was assessed in >11.000 adults from four health examination studies of randomly invited residents in the Copenhagen region conducted in 1990-1991, 2011-2012, 2012-2015, and 2016-2017. Alpha-gal sensitization was defined as serum specific IgE (sIgE) to alpha-gal ≥0.1 kUA/L; ≥0.35 kUA/L; ≥0.7 kUA/L; ≥3.5 kUA/L. The population was characterized according to genetically determined ABO blood group, aeroallergen sensitization, and pets at home.
Results: The prevalence of sIgE to alpha-gal ≥0.1 kUA/L was 1.3% in 1990-1991, 3.7% in 2012-2015 and 3.2% in 2016-2017. Of those sensitized to alpha-gal >97% reported to consume red meat at least once a week, even for sIgE to alpha-gal ≥3.5 kUA/L. Male sex, older age, aeroallergen sensitization, cat at home, and blood group A were associated with increased odds of alpha-gal sensitization. The known protective effect of blood group B was confirmed.
Conclusion: In this general adult population, the prevalence of alpha-gal sensitization had doubled from 1990-1991 to 2016-2017. This could potentially be due to increased tick exposure and an increased atopic predisposition.
Keywords: alpha‐gal syndrome; blood group a; epidemiology; galactose‐alpha‐1,3‐galactose; red meat allergy; tick bites.
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Conflict of interest statement
Katja Biering Leth‐Møller has received a lecture fee from Thermo Fisher Scientific. Marianne van Hage has received lecture fees from Thermo Fisher Scientific and Astra Zeneca outside the submitted work. Christian Vestergaard has received speaker honorarium/participated in Add Borads/been investigator for Abbvie, Pfizer, Sanofi, Leo Pharma, OM pharma, Pierre Fabre, Almirall, Astra Zeneca, Eli Lilly, Novartis. Flemming Madsen has received a travel grant from Orion Pharma. With no relation to the present manuscript, Simon Francis Thomsen has received research support from Janssen, LEO Pharma, Novartis, Sanofi and UCB, and has been a speaker/consultant for Abbvie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB, and Union therapeutics. Danijela Apostolovic, Jennifer Astrup Sørensen, Lene Jung Kjær, Torben Hansen, Anna Jonsson, and Allan Linneberg and have no conflict of interest.
Figures


References
-
- Kiewiet MBG, Apostolovic D, Starkhammar M, Grundstrom J, Hamsten C, van Hage M. Clinical and serological characterization of the alpha‐gal syndrome‐importance of atopy for symptom severity in a European cohort. J Allergy Clin Immunol Pract. 2020;8(6):2027‐2034. doi:10.1016/j.jaip.2020.02.016 - DOI - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous